$4.03 Billion in Sales Expected for Teva Pharmaceutical Industries Limited (NYSE:TEVA) This Quarter

Equities analysts expect that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce sales of $4.03 billion for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $4.01 billion to $4.10 billion. Teva Pharmaceutical Industries reported sales of $3.87 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 4.1%. The business is expected to announce its next earnings results on Wednesday, August 4th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $16.57 billion for the current financial year, with estimates ranging from $16.49 billion to $16.72 billion. For the next year, analysts anticipate that the company will post sales of $16.77 billion, with estimates ranging from $16.39 billion to $17.08 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, April 28th. The company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.08. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. The business had revenue of $3.98 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the previous year, the firm earned $0.76 EPS. The firm’s revenue was down 8.6% compared to the same quarter last year.

A number of analysts recently commented on TEVA shares. TheStreet upgraded Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a report on Monday, April 5th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $10.00 price target on shares of Teva Pharmaceutical Industries in a research note on Sunday, March 14th. Finally, UBS Group reissued a “neutral” rating and issued a $11.00 target price (down previously from $15.00) on shares of Teva Pharmaceutical Industries in a research note on Monday. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average target price of $11.58.

Teva Pharmaceutical Industries stock remained flat at $$10.25 during mid-day trading on Friday. The company’s stock had a trading volume of 462,327 shares, compared to its average volume of 9,512,450. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.00 and a quick ratio of 0.63. Teva Pharmaceutical Industries has a 12-month low of $8.44 and a 12-month high of $13.30. The company has a fifty day simple moving average of $10.87 and a 200-day simple moving average of $10.65. The stock has a market cap of $11.19 billion, a price-to-earnings ratio of -2.84, a PEG ratio of 0.87 and a beta of 1.49.

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 127,244 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 16th. The shares were sold at an average price of $11.22, for a total value of $1,427,677.68. Following the transaction, the insider now directly owns 20,598 shares of the company’s stock, valued at $231,109.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.56% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Psagot Investment House Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 9.8% during the fourth quarter. Psagot Investment House Ltd. now owns 4,926,904 shares of the company’s stock valued at $47,545,000 after buying an additional 440,810 shares during the last quarter. Bellecapital International Ltd. lifted its position in Teva Pharmaceutical Industries by 63.1% during the fourth quarter. Bellecapital International Ltd. now owns 26,100 shares of the company’s stock valued at $252,000 after purchasing an additional 10,100 shares during the period. Ayalon Holdings Ltd. acquired a new position in Teva Pharmaceutical Industries during the first quarter valued at $26,000. Vontobel Holding Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $39,104,000. Finally, Squarepoint Ops LLC acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $1,016,000. 51.20% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Debt-To-Equity Ratio

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.